Over the last three years, he has been an integral part of the firm's growth and business leaders initiatives, identifying new solutions for the firm's clients and network.
(L to R): Stephen Rupnarian, Partner, Tax Advisory, Collins Barrow Toronto LLP; Enzo Testa, Practice Area Leader, Tax Advisory, Collins Barrow Toronto LLP (CNW Group/Collins Barrow Toronto)
(L to R): Tim Zimmerman, Partner, Litigation Accounting and Valuation Services, Collins Barrow Toronto Valuations Inc.; Ian Wollach, Practice Area Leader, Litigation Accounting and Valuation ...Services, Collins Barrow Toronto Valuations Inc. (CNW Group/Collins Barrow Toronto)
"Tim has continuously demonstrated his leadership in the marketplace and in our business leaders program," says Ian Wollach, leader of the Litigation Accounting and Valuation Services practice.
Topics under discussion include: the perils and pitfalls of renunciation, the opportunities and benefits of relinquishment, streamlined filing procedures, and the legality of the Canadian/U.S.
"I look forward to this opportunity to work with the OBA and CPA Ontario on such a uniquely informative program," John Sinclair explained. "This is a valuable opportunity to learn more about the ...effect of IRS regulations on Canadian citizens, and to connect with professionals in accounting and law."
A working group supported by the Office of Rare Diseases of the National Institutes of Health formulated neuropathologic criteria for corticobasal degeneration (CBD) that were subsequently validated ...by an independent group of neuropathologists. The criteria do not require a specific clinical phenotype, since CBD can have diverse clinical presentations, such as progressive asymmetrical rigidity and apraxia, progressive aphasia, or frontal lobe dementia. Cortical atrophy, ballooned neurons, and degeneration of the substantia nigra have been emphasized in previous descriptions and are present in CBD, but the present criteria emphasize tau-immunoreactive lesions in neurons, glia, and cell processes in the neuropathologic diagnosis of CBD. The minimal pathologic features for CBD are cortical and striatal tau-positive neuronal and glial lesions, especially astrocytic plaques and thread-like lesions in both white matter and gray matter, along with neuronal loss in focal cortical regions and in the substantia nigra. The methods required to make this diagnosis include histologic stains to assess neuronal loss, spongiosis and ballooned neurons, and a method to detect tau-positive neuronal and glial lesions. Use of either the Gallyas silver staining method or immunostains with sensitive tau antibodies is acceptable. In cases where ballooned neurons are sparse or difficult to detect, immunostaining for phospho-neurofilament or α-B-crystallin may prove helpful. Methods to assess Alzheimer-type pathology and Lewy body pathology are necessary to rule out other causes of dementia and Parkinsonism. Using these criteria provides good differentiation of CBD from other tauopathies, except frontotemporal dementia and Parkinsonism linked to chromosome 17, where additional clinical or molecular genetic information is required to make an accurate diagnosis.
"I'm pleased to be offering municipalities valuable insight on GST/HST legislation as it pertains to their sector," said CB Toronto Partner Altaf Sarangi, who will speak on Thursday, September 22 at ...1:30 p.m. "From ITC allocation methodologies to real property elections and increased CRA...
PDF